29/10/2025 Merck's perioperative Keytruda regimen received approval from the EC for LA SCCHN with PD-L1 CPS ≥1 ( Ref ) The European Commission (EC) has approved Merck & Co./MSD's pembrolizumab (anti-PD-1) single agent as a neoadjuvant Tx followed by adjuvant pembrolizumab + RT with or without cisplatin after surgery, and then as a single agent for adults with resectable locally advanced SCCHN with PD-L1 CPS ≥1. The approval follows a positive CHMP opinion, and is based on res

28/10/2025 Alphamab Oncology's JSKN003 received the FDA fast track designation for PROC ( Ref ) The US FDA granted the fast track designation to Alphamab Oncology's JSKN003 (biparatopic HER2-targeting antibody-drug conjugate) for the treatment of advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (PROC). To note, in Sep'24, Alphamab  entered a licensing agreement with JMT-Bio Technology (a wholly-

Renal cell carcinoma (RCC) stands as the predominant form of kidney cancer, comprising about 90% of kidney cancer cases. It accounts for...

Thyroid Cancer, despite a good prognosis, has been a cause of concern over the past years. Thyroid Cancer shows no symptoms in the early stage, but its increasing rate of occurrence indicates the need for further diagnostic and therapeutic options. In observance of Thyroid Cancer Awareness month, Oncofocus is pleased to present an infographic highlighting the key options with a glimpse of the emerging therapies in the Thyroid cancer treatment paradigm.

In observance of Sarcoma Awareness Month, Oncofocus is pleased to present a user-friendly infographic. This comprehensive visual presentation aims to elucidate crucial aspects such as epidemiology, key treatment options, and emerging therapies related to sarcoma. By staying informed and actively participating in sharing this publicly accessible infographic, we can collectively raise awareness about sarcoma and its implications. Together, let us make a positive impact during S